Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Low Fat Cheese Market Growth & Trends
The global low fat cheese market size is anticipated to reach USD 136.06 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 3.5% from 2024 to 2030. Growing awareness about obesity, higher cholesterol among the consumers, along with changing food preferences, are likely to fuel the market growth over the anticipated years.
According to the WHO, in 2016, over 340 million children and adolescents aged between 5 to19 years were reported overweight. Obesity is a growing concern amongst children, especially in regions such as APAC and North America. As a result of this, many global fast food vendors such as McDonald’s and Starbucks are promoting the food segments using low fat cheese such as ricotta, feta, and mozzarella as main ingredients to serve healthy products and retain the customer base.
Actors, celebrities, and bloggers across the globe have been seen endorsing healthy cuisines using low fat and low calories dairy products such as skinny baked mozzarella sticks and cheesy baked zucchini noodle casserole over social media such as Instagram and Facebook. This has resulted in growing health concerns and greater consumption of low fat cheese among the consumers.
Ricotta held the largest share of 34.3% in 2018. Ricotta is a variant that is mainly produced from cow’s milk. The texture of ricotta varies between soft and dry. Salted varieties including smoked cheese are profusely used in kitchen, whereas the unsalted types such as baked ricotta are consumed directly as appetizers or desserts.
Mozzarella sticks is the fastest growing product category, expanding at a CAGR of 4.0% over the forecast period. This growth is largely attributed to rapidly growing fast food business worldwide. Moreover, mozzarella sticks are considered to be a healthy low fat snacking cheese. These sticks are usually labeled with ‘part-skim’ tag and are a source of 6 grams of fat, along with 7 grams of protein, 86 calories, and more than 200 milligrams of calcium. Shredded mozzarella processed from part-skimmed milk is a popular choice for consumers as it melts easily over homemade pizza or grilled cheese sandwich. For instance, in 2017, Domino’s launched its first ever low fat variant of mozzarella in Australia, where the fat content was reduced by 25% after four years of extensive R&D in the same.
The store-based channel held a leading share in the market. This category includes hypermarkets and supermarkets, convenience stores, grocery shops, mixed retailers, food specialists, and independent small grocery stores. The store-based channel offers one-stop experience to customers. However, adoption of technology by consumers is increasing due to sale of low fat cheese via online distribution channels such as Grofers and Big Basket.
Europe held the largest share in 2018, followed by North America. Demand for low fat cheese is expected to boost in Europe due to booming fast food industry and rising consumer awareness. APAC is projected to expand at the fastest CAGR of 4.4% over the forecast period. The expected growth is attributed to high fast food consumption in the region, along with increased disposable per capita income in countries such as India and China.
Some of the key players operating in the global low fat cheese market are like DSM; Crystal Farms; Lactalis Group; Arla Foods; Kraft Foods Group, Inc.; Amul; Bongrain; and Britannia Industries. Companies are focusing on introducing new variants of low fat cheese in their dairy food segment to tap the growing health conscious consumers. For instance, Arla Foods have expanded its Arla brand portfolio with the launch of Arla Quark to promote low fat and tasty alternatives for ingredients such as ricotta, mascarpone, and other soft cheese.
Low Fat Cheese Market Report Highlights
Low Fat Cheese Market Growth & Trends
The global low fat cheese market size is anticipated to reach USD 136.06 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 3.5% from 2024 to 2030. Growing awareness about obesity, higher cholesterol among the consumers, along with changing food preferences, are likely to fuel the market growth over the anticipated years.
According to the WHO, in 2016, over 340 million children and adolescents aged between 5 to19 years were reported overweight. Obesity is a growing concern amongst children, especially in regions such as APAC and North America. As a result of this, many global fast food vendors such as McDonald’s and Starbucks are promoting the food segments using low fat cheese such as ricotta, feta, and mozzarella as main ingredients to serve healthy products and retain the customer base.
Actors, celebrities, and bloggers across the globe have been seen endorsing healthy cuisines using low fat and low calories dairy products such as skinny baked mozzarella sticks and cheesy baked zucchini noodle casserole over social media such as Instagram and Facebook. This has resulted in growing health concerns and greater consumption of low fat cheese among the consumers.
Ricotta held the largest share of 34.3% in 2018. Ricotta is a variant that is mainly produced from cow’s milk. The texture of ricotta varies between soft and dry. Salted varieties including smoked cheese are profusely used in kitchen, whereas the unsalted types such as baked ricotta are consumed directly as appetizers or desserts.
Mozzarella sticks is the fastest growing product category, expanding at a CAGR of 4.0% over the forecast period. This growth is largely attributed to rapidly growing fast food business worldwide. Moreover, mozzarella sticks are considered to be a healthy low fat snacking cheese. These sticks are usually labeled with ‘part-skim’ tag and are a source of 6 grams of fat, along with 7 grams of protein, 86 calories, and more than 200 milligrams of calcium. Shredded mozzarella processed from part-skimmed milk is a popular choice for consumers as it melts easily over homemade pizza or grilled cheese sandwich. For instance, in 2017, Domino’s launched its first ever low fat variant of mozzarella in Australia, where the fat content was reduced by 25% after four years of extensive R&D in the same.
The store-based channel held a leading share in the market. This category includes hypermarkets and supermarkets, convenience stores, grocery shops, mixed retailers, food specialists, and independent small grocery stores. The store-based channel offers one-stop experience to customers. However, adoption of technology by consumers is increasing due to sale of low fat cheese via online distribution channels such as Grofers and Big Basket.
Europe held the largest share in 2018, followed by North America. Demand for low fat cheese is expected to boost in Europe due to booming fast food industry and rising consumer awareness. APAC is projected to expand at the fastest CAGR of 4.4% over the forecast period. The expected growth is attributed to high fast food consumption in the region, along with increased disposable per capita income in countries such as India and China.
Some of the key players operating in the global low fat cheese market are like DSM; Crystal Farms; Lactalis Group; Arla Foods; Kraft Foods Group, Inc.; Amul; Bongrain; and Britannia Industries. Companies are focusing on introducing new variants of low fat cheese in their dairy food segment to tap the growing health conscious consumers. For instance, Arla Foods have expanded its Arla brand portfolio with the launch of Arla Quark to promote low fat and tasty alternatives for ingredients such as ricotta, mascarpone, and other soft cheese.
Low Fat Cheese Market Report Highlights
- Ricotta dominated the market and accounted for a market revenue share of 34.1% in 2023. Ricotta cheese naturally contains lower fat levels than many other cheese varieties.
- Mozzarella sticks segment is anticipated to register the fastest CAGR of 3.7% during the forecast period.
- Retail accounted for the largest market revenue share in 2023. Consumers prefer the ease of purchasing groceries from supermarkets, hypermarkets, and convenience stores where a wide range of low-fat cheese options are readily available.
- Europe low fat cheese market accounted for the largest market revenue share of 34.3% in 2023. Cultural preferences and culinary traditions in Europe have influenced the growth of the low-fat cheese market.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. LUNG CANCER DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Lung Cancer Diagnostics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
CHAPTER 4. LUNG CANCER DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, USD Billion, 2023 & 2030
4.3. Non-small Cell Lung Cancer
4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Small Cell Lung Cancer
4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. LUNG CANCER DIAGNOSTICS MARKET: TEST ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, USD Million, 2023 & 2030
5.3. CA Tests
5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. HER2 Tests
5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. ALK Tests
5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Angiogenesis Inhibitors
5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. EGFR Mutation Tests
5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. KRAS Mutation Tests
5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. LUNG CANCER DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, USD Million, 2023 & 2030
6.3. Hospitals and clinics
6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Diagnostic Laboratories
6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. LUNG CANCER DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Lung Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Thermo Fisher Scientific
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Illumina Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Agilent Technologies
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Qiagen
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Abbott
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bio-Rad
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Neogenomics Laboratories
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. bioMйrieux
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Myriad Genetics, Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. LUNG CANCER DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Lung Cancer Diagnostics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
CHAPTER 4. LUNG CANCER DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, USD Billion, 2023 & 2030
4.3. Non-small Cell Lung Cancer
4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Small Cell Lung Cancer
4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. LUNG CANCER DIAGNOSTICS MARKET: TEST ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, USD Million, 2023 & 2030
5.3. CA Tests
5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. HER2 Tests
5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. ALK Tests
5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Angiogenesis Inhibitors
5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. EGFR Mutation Tests
5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. KRAS Mutation Tests
5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. LUNG CANCER DIAGNOSTICS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, USD Million, 2023 & 2030
6.3. Hospitals and clinics
6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Diagnostic Laboratories
6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. LUNG CANCER DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Lung Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Thermo Fisher Scientific
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Illumina Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Agilent Technologies
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Qiagen
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Abbott
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bio-Rad
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Neogenomics Laboratories
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. bioMйrieux
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Myriad Genetics, Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
